CriticalProkinetic, peripheral dopamine D2 receptor antagonist×Atypical antipsychotics
Updated · Methodology
Mechanism
Domperidone is associated with QT prolongation. Epidemiological studies also link it to a higher risk of serious ventricular arrhythmias and sudden cardiac death, especially in people over 60, at doses above 30 mg a day, and with QT-prolonging drugs (domperidone summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). In clinical trials quetiapine did not cause a persistent increase in the QT interval. After marketing, however, QT prolongation has been reported with it both at therapeutic doses and in overdose (quetiapine SmPC, AEMPS, and label, US Food and Drug Administration, FDA). The Spanish domperidone SmPC explains that combinations with QT-prolonging drugs raise the risk of QT prolongation through pharmacodynamic or pharmacokinetic interactions (domperidone SmPC, AEMPS). The liver metabolises both drugs mainly through CYP3A4 (domperidone and quetiapine SmPCs, AEMPS). According to its US label, quetiapine does not inhibit the major CYP enzymes, CYP3A4 included (FDA quetiapine label). The documents give no data on how one drug changes the level of the other.
Symptoms
QT prolongation itself causes no symptoms and shows only on an electrocardiogram (ECG), while an arrhythmia causes palpitations, dizziness and fainting. With domperidone, QT prolongation and torsade de pointes have been reported very rarely (domperidone summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The Spanish quetiapine SmPC lists QT prolongation, fast heart rate and slow heart rate among its adverse reactions. Among the class effects of all neuroleptics, it lists QT prolongation, ventricular arrhythmia, unexplained sudden death, cardiac arrest and torsade de pointes (quetiapine SmPC, AEMPS). The risk of arrhythmia is higher with low or high potassium, low magnesium or a slow heart rate (domperidone SmPC, AEMPS).
Management
The combination is contraindicated. The Spanish domperidone summary of product characteristics (SmPC) contraindicates domperidone with QT-prolonging drugs, without a closed list (domperidone SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Quetiapine is not among the example antipsychotics in this SmPC. The warnings sections of its own SmPC and label, however, state that QT prolongation has been reported with it, even though clinical trials showed no persistent QT increase (quetiapine SmPC, AEMPS, and label, US Food and Drug Administration, FDA). The contraindication therefore covers quetiapine too. According to the US label, avoid quetiapine with drugs known to prolong the QT interval, in patients with a history of arrhythmias such as bradycardia, with low potassium or magnesium, and with congenital QT prolongation (FDA quetiapine label). The Spanish SmPC advises caution with such drugs, especially in older people and in congenital long QT syndrome, congestive heart failure, cardiac hypertrophy, and low potassium or magnesium (quetiapine SmPC, AEMPS). Domperidone is also contraindicated in known QT prolongation, significant electrolyte disturbances and heart disease such as congestive heart failure (domperidone SmPC, AEMPS). If domperidone and quetiapine have nevertheless been taken together and signs of arrhythmia appear, stop domperidone (domperidone SmPC, AEMPS).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Seroquel (quetiapine) prescribing information (2026)– FDA label, H2-Pharma, LLC, DailyMed setid 8ae62aaf-f8c5-417f-baac-0098369ca322, revised 04/2026, section 7
- AEMPS: Ficha técnica: Quetiapina, Seroquel 25 mg (nº registro 63054), secciones 4.3, 4.4 y 4.5 (2024)– AEMPS, CIMA, nº registro 63054, revisión 12/2024, secciones 4.3, 4.4 y 4.5
- AEMPS: Ficha técnica: Domperidona (nº registro 55411), sección 4.3 (2025)– AEMPS, CIMA, nº registro 55411 (Motilium 1 mg/ml suspensión oral, Esteve), revisión 09/2025, secciones 4.2, 4.3, 4.4 y 4.5